Table 1.
The clinical characteristics of patients
| Disease | AA | MDS | AA-PNH | PRCA | |||||
|---|---|---|---|---|---|---|---|---|---|
| Idiopathic | Thymoma associated | Autoimmune disease associated | Drug associated | Parvovirus associated* | T-LGLL associated | ||||
| No. of patients | 54 | 21 | 7 | 15 | 7 | 5 | 1 | 1 | 13 |
| Age, median (range), y | 60 (26-94) | 65 (26-83) | 37 (20-56) | 71 (39-82) | 48 (43-78) | 63 (58-67) | 65 | 49 | 71 (20-78) |
| Male, % | 51 | 40 | 29 | 10 | 33 | 67 | 0 | 100 | 27 |
| WBC, median (range), ×109/L | 2.9 (1.2-5.3) | 2.1 (0.5-7.9) | 2.4 (1.1-5.3) | 3.9 (2.3-5.1) | 4.8 (3.0-5.7) | 4.0 (2.3-6.7) | 2.9 | 10.9 | 6.7 (3.3-19.1) |
| Neutrophils, median (range), ×109/L | 1.3 (0.2-4.2) | 1 (0.04-5.1) | 2.5 (0.5-4.5) | 2.7 (0.9-3.3) | 3.1 (1.4-3.3) | 2.2 (1.5-4.7) | 1.5 | 8.7 | 1.9 (0.7-13.2) |
| Hemoglobin, median (range), g/L | 114 (38-160) | 94 (33-134) | 75 (50-119) | 62 (42-77) | 52 (40-66) | 66 (58-67) | 57 | 69 | 89 (48-100) |
| Platelets, median (range), ×109/L | 58 (6-232) | 83 (19-200) | 115 (25-180) | 300 (168-405) | 249 (213-417) | 208 (113-391) | 243 | 319 | 306 (222-584) |
| Follow-up duration, median (range), mo | 70 (1-1404) | 30 (7-324) | 153 (52-413) | 38 (1-300) | 6 (2-85) | 38 (30-204) | 1 | 134 | 44 (9-261) |
| Survival rate, % | 88 | 80 | 100 | 90 | 67 | 67 | 100 | 100 | 100 |
| AsPCR+, n (%) | 0 | 0 | 0 | 2 (13) | 1 (14) | 0 | 0 | 0 | 6 (46) |
Clinical data were obtained from Nagano and Kanazawa cohorts.
AsPCR, allele-specific polymerase chain reaction for STAT3 Y640F and/or D661Y mutation; WBC, white blood cell count.
*
Parvovirus B19 infection complicated by T-LGLL.